AdhexPharma
France 169 employees Updated 9 July 2026
AdhexPharma is a contract manufacturer based in France. Its GMP standing is certified by ANSM (FR), EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 14 June 2023 as VAI.
3
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 14 June 2023 VAI US FDA
- 19 July 2019 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| France, France | 3008426496 |
| 21300
Additional Details: Adhexpharma - 42/44 rue de Longvic, France | Not on file |
| Chenove, France | Not on file |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| ANSM (FR) | None | 5 |
| EMA | None | 1 |
| US FDA | None | 1 |
Scale
| Year | Revenue | Exports | Destinations |
| 2019 | $23.8M | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Comparing suppliers?
Choose your molecules and target markets. AdhexPharma comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 14 June 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates
- Company filings
- Revenue as reported